| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
1 Medical College of Wisconsin
2 UT Southwestern Medical Center @ Dallas
* To whom correspondence should be addressed. E-mail: ggross{at}mcw.edu.
Previously we demonstrated that 11,12- and 14,15-epoxyeicosatrienoic acids (EETs) produce reductions in myocardial infarct size. Although it is assumed that this effect of the EETs is due to a specific interaction with a membrane bound receptor, no data suggest that novel EET antagonists selectively block EET actions in dogs. Our goals were to investigate the effects of 11,12- and 14,15-EET, the EPHX2 inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), and the selective EET antagonist, 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) on infarct size in barbital anesthetized dogs. Furthermore, the effect of 14,15-EEZE on the cardioprotective actions of the mitochondrial KATP channel opener, diazoxide, was investigated. Both 11,12- and 14,15-EET reduced infarct size (expressed as a percent of the area at risk, IS/AAR) from 21.8 ± 1.6% to 8.7 ± 2.2% and 9.4 ± 1.3%, respectively. Similarly, AUDA significantly reduced IS/AAR from 21.8 ± 1.6% to 14.4 ± 1.2% (low dose) and 9.4 ± 1.8% (high dose), respectively. The combination of low dose AUDA with 14,15-EET further reduced IS/AAR to 5.8 ± 1.6% (P< 0.05). Diazoxide also reduced IS/AAR (10.2 ± 1.9%). In contrast, 14,15-EEZE had no effect on IS/AAR (21.0 ± 3.6%) but abolished the effect of 11,12-EET (17.8 ± 1.4%), 14,15-EET (19.2 ± 2.4%) and AUDA (19.3 ± 1.6%) but not diazoxide (10.4 ± 1.4%). These results suggest that activation of the EET pathway by exogenous EETs or indirectly by blocking EET metabolism produced marked cardioprotection. These data also suggest that 14,15-EEZE is not blocking the mito KATP channel.
This article has been cited by other articles:
|
|
 |
|
  Y. Chen, J. R. Falck, V. R. Tuniki, and W. B. Campbell 20-125Iodo-14,15-Epoxyeicosa-5(Z)-enoic Acid: a High-Affinity Radioligand Used to Characterize the Epoxyeicosatrienoic Acid Antagonist Binding Site J. Pharmacol. Exp. Ther., December 1, 2009; 331(3): 1137 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, H. El-Sikhry, K. R. Chaudhary, S. N. Batchu, A. Shayeganpour, T. O. Jukar, J. A. Bradbury, J. P. Graves, L. M. DeGraff, P. Myers, et al. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H37 - H46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Gross, K. M. Gauthier, J. Moore, W. B. Campbell, J. R. Falck, and K. Nithipatikom Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H47 - H52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Spector Arachidonic acid cytochrome P450 epoxygenase pathway J. Lipid Res., April 1, 2009; 50(Supplement): S52 - S56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Motoki, M. J. Merkel, W. H. Packwood, Z. Cao, L. Liu, J. Iliff, N. J. Alkayed, and D. M. Van Winkle Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2128 - H2134. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
